Tag: licensing
-
FDA Grants Orphan Drug Status for ALS Candidate
BrainStorm Cell Therapeutics Inc. in Petach Tikvah, Israel says the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s NurOwn adult stem cell product candidate for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease. ALS is a progressive neurodegenerative disease of nerve cells in the…
-
Fuel Cell Developer Relocates Near Nanotech Researcher
Bing Energy Inc., a manufacturer of components for polymer electrolyte membrane fuel cells, is moving its headquarters from California to Florida to work with a university researcher in nanotechnology. The company had already licensed the research of Jim Zheng, an engineering professor at Florida State University in Tallahassee, whose work involves nanosensors, energy storage, and…
-
Univ. Developing Prototype Air Passenger Liquid Scanner
A University of California at Davis professor is building a magnetic resonance device that can scan unopened bottles carried on airplanes by passengers. Matthew Augustine, a member of the UC Davis chemistry faculty, originally developed the technology to check the quality of wine. Augustine began experimenting with the technology some years ago to check sealed…
-
Endo Pharma, Orion Corp. to Advance Cancer Drugs
Endo Pharmaceuticals in Chadds Ford, Pennsylvania and Orion Corporation in Espoo, Finland said today they have a collaboration agreement for drug research and development in oncology. The partnership aims to advance eight discovery-phase cancer drug candidates by combining their relevant R&D programs. The collaboration also gives each company exclusive licensing rights to the other’s development-ready…
-
University, Start Up Develop Anti-Counterfeit Technology
A student at Simon Fraser University (SFU) in Burnaby, British Columbia, Canada researched a new method based on nanotechnology for stopping counterfeiters, which has led to the founding of a new company to develop the product. Nanotechnology uses materials at nanometer scale, with one nanometer equal to one billionth of a meter. Clint Landrock, an…
-
Bristol-Myers Squibb, Biotech Partner on Alzheimer’s Test
Opko Health Inc., a biotechnology company in Miami, Florida, said today it has a collaboration agreement with the drug manufacturer Bristol-Myers Squibb Company for Opko’s diagnostic test technology. Opko’s blood tests are being developed from its technology that identifies biomarkers for a range of diseases including neurodegenerative disorders. Part of the project calls for Opko…
-
Univ. Engineers Develop New Sewage Treatment Device
Research engineers at University of Utah in Salt Lake City have developed and commercialized an alternative device to help growing communities deal with sewage treatment. The device, known as Poo-Gloos because of their igloo-like shape (pictured right), supplement wastewater lagoons often used for sewage treatment, particularly in small, rural towns. Kraig Johnson and research colleagues…
-
Spirogen, Genentech Partner on Anti-Cancer Therapies
Spirogen Ltd. a London, U.K. biotechnology company, announced a multi-year research collaboration and license agreement with Genentech, a Roche Group company, to discover and develop antibody drug conjugates (ADCs) as potential anti-cancer agents. The collaboration will make use of Spirogen’s pyrrolobenzodiazepine (PBD) drugs, a group of natural antibiotics, and associated linking technology. Under the agreement,…
-
National Lab Signs Two Auto Battery Licensing Deals
Argonne National Laboratory in Argonne, Illinois, part of the U.S. Department of Energy, announced two licensing agreements today (6 January 2011) for its cathode material technology used in electric vehicle lithium-ion (Li-ion) batteries. The deals are with or involve cars made by General Motors. The first agreement, with General Motors, involves the worldwide licensing of…
-
Pharma, Biotech Ink Deal on Anti-Inflammatory Candidate
XOMA Ltd., a biotechnology company in Berkeley, California, and Les Laboratoires Servier a French pharmaceutical company, announced an agreement to develop and commercialize XOMA 052, XOMA’s anti-inflammatory drug candidate. XOMA 052 is designed to inhibit the pro-inflammatory cytokine interleukin-1 beta believed to be a primary trigger of pathologic inflammation in multiple diseases. Under the agreement,…